Elafibranor
Chemical compound
- A05AX06 (WHO)
- 2-[2,6 Dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)-propenyl]phenoxyl]-2-methylpropanoic acid[1]
- 923978-27-2
- 9864881
- 8040573
- 2J3H5C81A5
- DTXSID601045330
- Interactive image
- O=C(O)C(Oc1c(cc(cc1C)\C=C\C(=O)c2ccc(SC)cc2)C)(C)C
InChI
- InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
- Key:AFLFKFHDSCQHOL-IZZDOVSWSA-N
Elafibranor (INN,[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[3][4][5]
Elafibranor is a dual PPARα/δ agonist.[6][7]
See also
- MBX-8025/Seladelpar
- Resveratrol
- Telmisartan
References
- ^ Cariou B, Zaïr Y, Staels B, Bruckert E (September 2011). "Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism". Diabetes Care. 34 (9): 2008–14. doi:10.2337/dc11-0093. PMC 3161281. PMID 21816979.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. p. 10. Archived (PDF) from the original on 10 November 2016. Retrieved 9 November 2016.
- ^ "Advanced Compound Status" (Press release). Genfit. Archived from the original on 2013-04-11.
- ^ "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). Archived (PDF) from the original on 10 July 2021. Retrieved 31 Mar 2013.
- ^ Cariou B, Staels B (October 2014). "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs. 23 (10): 1441–8. doi:10.1517/13543784.2014.954034. PMID 25164277. S2CID 3190253.
- ^ US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641" (PDF). Retrieved 31 Mar 2013.
- ^ Vázquez-Carrera, M. (2012). "GFT-505" (PDF). Drugs of the Future. 37 (8): 555–559. doi:10.1358/dof.2012.037.08.1835977. S2CID 258323049.[permanent dead link]
External links
- Genfit Pharmaceutical
- NashBiotechs Several articles on drug candidates in NASH
- v
- t
- e
PPARTooltip Peroxisome proliferator-activated receptor modulators
- Agonists: 15-HETE
- 15-HpETE
- Aleglitazar
- Aluminium clofibrate
- Arachidonic acid
- Bezafibrate
- Chiglitazar
- Clofibrate
- CP-775146
- Daidzein
- DHEA (prasterone) (in rodents)
- Elafibranor
- Etomoxir
- Fenofibrate
- Genistein
- Gemfibrozil
- GW-7647
- Lanifibranor
- Leukotriene B4
- LG-101506
- LG-100754
- Lobeglitazone
- Muraglitazar
- Oleylethanolamide
- Palmitoylethanolamide
- Pemafibrate
- Perfluorononanoic acid
- Perfluorooctanoic acid
- Pioglitazone
- Saroglitazar
- Sodelglitazar
- Tesaglitazar
- Tetradecylthioacetic acid
- Troglitazone
- WY-14643
- Antagonists: GW-6471
- MK-886
- Agonists: 15-HETE
- 15-HpETE
- Arachidonic acid
- Bezafibrate
- Daidzein
- Elafibranor
- Fonadelpar
- Genistein
- GW-0742
- GW-501516
- L-165,041
- Lanifibranor
- LG-101506
- Seladelpar
- Sodelglitazar
- Tetradecylthioacetic acid
- Antagonists: FH-535
- GSK-0660
- GSK-3787
- Agonists: 5-Oxo-ETE
- 5-Oxo-15-hydroxy-ETE
- 15-Deoxy-Δ12,14-prostaglandin J2
- 15-HETE
- 15-HpETE
- Aleglitazar
- Arachidonic acid
- Balaglitazone
- Berberine
- Bezafibrate
- Cannabidiol
- Cevoglitazar
- Chiglitazar
- Ciglitazone
- Daidzein
- Darglitazone
- Edaglitazone
- Efatutazone
- Englitazone
- Etalocib
- Farglitazar
- Genistein
- GW-1929
- Ibuprofen
- Imiglitazar
- Indeglitazar
- Lanifibranor
- LG-100268
- LG-100754
- LG-101506
- Lobeglitazone
- Muraglitazar (muroglitazar)
- nTZDpa
- Naveglitazar
- Netoglitazone
- Oxeglitazar
- Peliglitazar
- Pemaglitazar
- Perfluorononanoic acid
- Pioglitazone
- Prostaglandin J2
- Ragaglitazar
- Reglitazar
- Rivoglitazone
- Rosiglitazone
- RS5444
- Saroglitazar
- Sipoglitazar
- Sodelglitazar
- Telmisartan
- Tesaglitazar
- Troglitazone
- Antagonists: FH-535
- GW-9662
- SR-202
- T-0070907
- Unknown: SR-1664
- See also
- Receptor/signaling modulators
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e